149 related articles for article (PubMed ID: 38281466)
1. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
Boucher L; Rozalska L; Sorel N; Olivier G; Hernanz MPG; Cayssials E; Raimbault A; Chomel JC
Leuk Res; 2024 Feb; 137():107439. PubMed ID: 38281466
[No Abstract] [Full Text] [Related]
2. Genetic landscape of chronic myeloid leukemia.
Ochi Y
Int J Hematol; 2023 Jan; 117(1):30-36. PubMed ID: 36477676
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.
Kaehler M; Cascorbi I
Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601
[TBL] [Abstract][Full Text] [Related]
4. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
5. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia.
Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF
Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178
[TBL] [Abstract][Full Text] [Related]
7. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
8. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
9. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
Bavaro L; Martelli M; Cavo M; Soverini S
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817512
[TBL] [Abstract][Full Text] [Related]
12. Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases.
Chen Y; Wang Q; Cen J; Xu C; Tao TT; Xie J; Shen W; Gong Y; Pan J; Yao L
Mol Carcinog; 2023 Feb; 62(2):117-121. PubMed ID: 36321418
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
[TBL] [Abstract][Full Text] [Related]
14. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
15. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S; Saikia T; Pany A; Das B
Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
[TBL] [Abstract][Full Text] [Related]
18. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph
Peter B; Eisenwort G; Sadovnik I; Bauer K; Willmann M; Rülicke T; Berger D; Stefanzl G; Greiner G; Hoermann G; Keller A; Wolf D; Čulen M; Winter GE; Hoffmann T; Schiefer AI; Sperr WR; Zuber J; Mayer J; Valent P
Am J Hematol; 2022 Sep; 97(9):1215-1225. PubMed ID: 35794848
[TBL] [Abstract][Full Text] [Related]
19. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
20. [Next treatment for TKI-resistant CML].
Takahashi N
Rinsho Ketsueki; 2023; 64(9):981-987. PubMed ID: 37793874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
